Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)
A legfontosabb adatok
- Ki végzi
- Beijing 302 Hospital
- Hol
- Kína7 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 140 fő, tervezett
- Kezdés
- 2024. jún. 27.
- Várható befejezés
- 2027. jún. 20.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- UC-MSCs
- Placebo(solution without UC-MSCs)
- A regiszteradat frissítve
- 2024. október 18.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with decompensated liver cirrhosis. This means cirrhosis with at least one serious complication. It tests umbilical cord stem cells against a placebo.
- Életkor
- 18 to 75 years
- Nem
- Male or female
- A betegség stádiuma
- Decompensated liver cirrhosis, with at least one serious complication such as bleeding from swollen veins in the gullet or stomach, confusion from liver failure (hepatic encephalopathy), fluid in the belly (ascites) or belly infection. MELD score of 15 to 30 points.
- Korábbi kezelés
- People with hepatitis B or C cirrhosis must have had antiviral treatment for at least 12 months. People with autoimmune hepatitis must have had corticosteroids for at least 6 months. People who had stem cell therapy before cannot join.
- Biomarker vagy leletérték
- For hepatitis B, HBV DNA must be below the detection limit. For hepatitis C, HCV RNA must be below the detection limit.
A részvétel fő kizáró okai
- Active variceal bleeding, overt hepatic encephalopathy, ascites that does not respond to treatment, or hepatorenal syndrome within 1 month before screening
- TIPS shunt placed within 6 months, or a liver transplant planned within three months
- Cancer within 5 years, except some skin cancers or carcinoma in situ that were fully treated
- Earlier major organ transplant, positive HIV or syphilis test, or serious heart, lung, kidney or blood disease
- Pregnancy, breastfeeding or plans to have a child during the trial and for 6 months after
A regiszter feltételei, szó szerint
Mind a 25 feltétel megnézéseKevesebb
Ki vehet részt
- Willing to provide written informed consent
- Aged 18 to 75 years (including 18 and 75 years), male or female
- Patients diagnosed with decompensated liver cirrhosis based on clinical findings, laboratory tests, imaging findings and/or representative pathological findings (decompensated liver cirrhosis is defined as the occurrence of at least one serious complication, including esophageal and gastric varices bleeding, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis and other serious complications)
- The Model for End-stage Liver Disease (MELD) score 15 to 30 points
Ki nem vehet részt
- Appearance of active variceal bleeding, overt hepatic encephalopathy (HE), refractory ascites or hepatorenal syndrome within 1 month prior to screening visit
- Patients under treatment with corticosteroids for autoimmune hepatitis for less than 6 months
- Trans-jugular intrahepatic portosystemic shunts (TIPS) insertion within 6 months prior to study inclusion
- Patients with surgical history such as splenic cut-off flow
- Patients with malignant tumors within 5 years, except those with basal cell carcinoma, squamous cell carcinoma and/or carcinoma in situ who had received curative treatment and curative resection
- Patients with a prior history of major organ transplantation or complicated with significant disease of heart, lung, kidney, blood, endocrine and other systems
- Drug abuse, drug dependence and patients who receive methadone treatment or with psychosis
- Highly allergic, or have a history of severe allergies, known severe allergies to the investigational drug or any of the excipients
- Patients who had previously received stem cell therapy or were intolerant to cell therapy
- Uncontrolled severe infection within 2 weeks of screening
- Patients with hepatitis B virus-related decompensated liver cirrhosis may discontinue antiviral therapy during the study, or those who with antiviral therapy for HBV for less than 12 months, or hepatitis B virus (HBV) DNA ≥ detection limit at the time of screening
- Patients with hepatitis C virus-related decompensated liver cirrhosis may discontinue antiviral therapy during the study, or those who with antiviral therapy for HCV for less than 12 months, or hepatitis C virus (HCV) RNA ≥ detection limit at the time of screening (except HCV RNA< detection limit without any antiviral treatment)
- Against the human immunodeficiency virus antibody (Anti - HIV) or syphilis antibody test results were positive
- History of pulmonary embolism
- Any other clinical condition which the investigator considers would make the patient unsuitable for the trial
- Significant renal insufficiency (serum creatinine ≥ 1.2 times upper normal limit); Severe electrolyte abnormality (serum sodium level < 125 mmol/L); Severe leukopenia (white blood cell count < 1 × 10E9/L)
- Active drinkers with alcohol-related decompensated cirrhosis are unwilling to stop alcohol abuse after inclusion
- Patients with biliary obstruction, or portal vein spongiosis
- Pregnancy, lactation or with recent fertility plan during the test and 6 months after the test
- The proposed line of liver transplants within three months
- Participants in other clinical trials within the last 3 months
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Decompensated cirrhosis has a high overall mortality rate. There is a large unmet need for safe and alternative therapeutic potions. This clinical trial is to inspect the efficiency and safety of mesenchymal stem cells (MSCs) therapy for decompensated cirrhosis.
A vizsgálat 2 csoportja
- Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)A vizsgált kezelés
UC-MSCs plus standard of care (SOC).
Kezelés: UC-MSCs
- PlaceboPlacebo, összehasonlításként
Placebo plus SOC.
Kezelés: Placebo(solution without UC-MSCs)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Decompensated Cirrhosis Patients(MSC-DLC-2)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT05224960: ki vehet részt
- A regiszteradat frissítve
- 2024. október 18.